Stereotaxis is trading at $0.93, up +10.15%, alongside a broad market rally; no company-specific catalyst has been identified. - Supplied market context reports major U.S. indices rose more than 1.7% on November 4; premarket coverage also listed Stereotaxis among healthcare stock gainers. - Stereotaxis’s latest listed release, on November 2, covered Robocath study results. Third-quarter results are scheduled for November 10; neither item is confirmed as the cause of the move.